Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.
Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs
Marina Fabbi and Silvano Ferrini
IL-15 is an immune-enhancing cytokine belonging to the IL-2 family, which supports survival, proliferation and functional activities of NK, NK-T, T and B cells. Moreover, IL-15 may support the growth and survival of different lymphoid malignancies, suggesting that targeting of the IL-15/IL-15R system or its downstream signaling cascade may result in therapeutic effects, in these tumors. On the other hand, given its immune-enhancing activities IL-15 has been considered a good candidate for cancer immunotherapy. Indeed, IL-15 or IL-15 super agonists have shown anti-tumor activity in several animal tumor models either alone or combined with other immune-enhancing molecules. Therefore, clinical trials of IL-15 or IL-15 super-agonists are ongoing in different cancers. Here we will summarize the biological features of the IL-15/IL-15R system and discuss its duality in tumor biology and the potential applications of IL-15 agonists and antagonists in cancer.